While drug-related periostitis has been known of for many years, the specific association of diffuse periostitis with voriconazole (most frequently in transplant patients) has only been recently explicitly addressed in the literature. Recognition of the radiologic and clinical manifestations of voriconazole-related periostitis is important for helping to narrow an otherwise broad differential diagnosis. We present two cases that illustrate different radiologic presentations of this painful cause of diffuse periostitis. Case 1 features a 60 year-old woman with a history of orthotopic heart transplant who was hospitalized for "full body pain" with progressively worsening bone tenderness involving the humeri, knees, femurs, hips, and hands. Case 2 describes a 48 year-old man with a history of acute lymphoblastic leukemia status post stem cell transplant who presented with diffuse arthralgias involving bilateral ankles, knees, wrists, and elbows.
CASE REPORT
Case 1 A 60 year-old woman with previous history of orthotopic heart transplant (eight months prior to admission) with mild acute cellular rejection was admitted with a two week history of refractory polyarticular pain with associated fever and malaise. There was no associated history of morning stiffness. Physical exam demonstrated normal muscular strength and tone and all joints with full range of motion. Both knees demonstrated minimal effusions however the right greater than left knees were exquisitely tender to palpation with the remainder of the joints similarly sensitive. Of note the patient had started on prophylactic antifungal therapy with voriconazole five months prior to the most recent presentation. Additionally, the patient had been hospitalized six weeks prior to the most recent presentation and treated for presumptive pulmonary aspergillosis with a therapeutic course of voriconazole. The patient remained on voriconazole until the time of the case presentation. Laboratory values were as follows: alkaline phosphatase was markedly elevated at 304 (reference range 29-111 U/L) and had been steadily increasing over the four months prior to hospitalization. However, other serologies were within normal limits. Creatine kinase was 29 (normal reference range 39-189 U/L). Antinuclear antibody (ANA) was < 40, double-stranded DNA was < 30 IU/mL, and anti-histone antibody was <1.0, all within normal limits. White blood cell count was normal.
Noncontrast computed tomography (CT) of the chest was performed shortly prior to admission which demonstrated exuberant periosteal bone formation involving several leftsided ribs (Figure 1 ). Plain radiographs obtained at the same time demonstrated extensive periosteal bone formation along the proximal medial cortex of the left humerus ( Figure 2 ). Additional plain radiographs at admission demonstrated periostitis of the proximal femoral shafts and humeral shafts ( Figure 2 ) which correlated with evidence of diffuse abnormal uptake involving the clavicles, left sixth and seventh ribs, bilateral proximal humeri, bilateral proximal femurs, proximal tibial diaphyses, right third proximal phalanx, and right fifth metacarpal on Tc-99m MDP whole body bone scan (Figure 3 ). On the basis of the laboratory and radiological imaging findings, voriconazole-related periostitis was suspected and CASE REPORT this medication was discontinued. Secondary hypertrophic osteoarthropathy was considered as an alternative diagnosis, however, given the specific history of voriconazole use, the presentation was highly suspicious for voriconazole-related periostitis. The patient reported improvement in symptoms soon after cessation of voriconazole. Follow-up noncontrast chest CT ( Figure 1 ) and bone scan (Figure 3 ), three and fourth months respectively following the admission, demonstrated marked interval resolution of previously seen abnormal periostitis.
Case 2 A 48 year-old man with history of acute lymphocytic leukemia status post stem cell transplant 10 months prior to onset of symptoms presented with joint pain involving bilateral elbows, ankles, knees, and wrists. He denied any history of erythema or swelling of joints. The pain was constant, severe, and disabling to the point that the patient was bedridden secondary to the pain. The patient began to take dilaudid which provided some temporary relief but the pain did not resolve. A course of corticosteroids provided temporary resolution of pain but the symptoms returned when the dose was tapered. His most recent bone marrow biopsy confirmed remission of leukemia. Physical exam was remarkable for bilateral olecranon hyperostosis, limited rotation of bilateral elbows with otherwise full range of motion. Laboratory values were as follows: alkaline phosphatase was markedly elevated at 245 (reference range 29-111 U/L). Erythrocyte sedimentation rate was elevated at 93 (normal reference range 0-10 mm/h). C-Reactive protein was elevated at 34.6 (normal reference range <6.3 mg/L). Serologies for anti-nuclear antibodies, serum rheumatoid factor, and double-stranded DNA antibody were all negative. Other serologies were within normal limits. Creatine kinase was 29 (normal reference range 39-189 U/L). ANA was < 40, double-stranded DNA was < 30 IU/mL, and anti-histone antibody was <1.0, all within normal limits. White blood cell count was normal.
Plain radiographs of the elbow demonstrated extensive periosteal bone formation along the bilateral distal humeri, proximal ulnae, and the proximal radial and ulnar diaphysis ( Figure 4 ). No significant degenerative changes or signs of an inflammatory arthropathy were seen. No juxta-articular osteopenia was noted. Additional radiographs of the hands demonstrated periosteal bone formation along the right fifth metacarpal, the distal right ulna and radius, the left second and fifth metacarpal, and the proximal first phalanges bilaterally ( Figure 5 ). Voriconazole was discontinued. The patient reported dramatic improvement in pain since stopping voriconazole with significantly less pain medication requirements.
Diffuse bone pain can be seen in a wide variety of conditions including multiple metabolic/inflammatory processes along with primary and metastatic bone tumors. Infection can also at times be a confounding diagnostic consideration. The specific subset of patients with diffuse periostitis is noteworthy because of the extremely severe pain that these patients can experience owing to the abundant innervation of the periosteum [1] .
Voriconazole is a powerful second-generation triazole antifungal agent approved by the Food and Drug Administration in 2002. The drug is similar to fluconazole, however, was created by substituting a fluorinated pyrimidine in lieu of the triazole moiety, leading to expanded antifungal properties [2] . Voriconazole is commonly used in immunocompromised patients to treat both invasive aspergillosis and candidemia with comparable efficacy to regimens of intravenous amphotericin B and/or fluconazole [2, 3] . With more than 25,000 lung transplants performed worldwide and an incidence of invasive aspergillus infection from 6-17% (with a 50-100% mortality rate), the powerful voriconazole has become an attractive therapy for both the treatment of and prophylaxis against serious fungal infections [4] [5] [6] . The most common side effect of voriconazole is a transient visual disturbance. Less common side effects include rash and elevations in hepatic transaminases [2] .
Several case reports have recently documented periostitis in the setting of long-term voriconazole therapy [7] . Wang et al initially described periostitis associated with voriconazole in lung transplant patients [7] . Periostitis on bone scans and plain radiographs was characteristic, in association with severe bone pain, absence of clubbing, and elevated alkaline phosphatase. These findings resolved in all patients following voriconazole discontinuation. A similar series by Chen and Mulligan reported dense and irregular periosteal reaction in lung transplant patients on chronic voriconazole in contrast to the smooth and single layer periostitis described in lung-cancerassociated hypertrophic osteoarthropathy. Additional case reports have recently described this phenomenon of radiographically dramatic periostitis in the setting of chronic voriconazole use which completely resolves upon discontinuation of the medication [8] [9] [10] [11] [12] .
The precise mechanism of periostitis in association with voriconazole therapy is unclear however recent reports have suggested that fluoride toxicity might be the underlying etiology. Periostitis deformans in the setting of bone fluorosis was first described by Soriano in 1952 with subsequent description of the radiological findings of dramatic "scleroatrophic osteitis" [13, 14] . Fluoride induces bone formation by stimulating osteoblasts [15] . The radiological findings in many of the reported cases of voriconazole-induced periostitis are similar in appearance to the initial descriptions of periostitis deformans in the setting of fluoride excess, first establishing the possible link. More recently Wermers et al studied plasma fluoride levels in 10 adult post-transplant patients who had received voriconazole for at least 6 months and compared to 10 patients who had not received voriconazole. All subjects who received voriconazole had markedly elevated plasma fluoride levels and no subjects in the control group had elevated levels (14.32 µmol/L ± 6.41 compared to 2.54 ± 0.67 µmol/L, p<0.001) [16] . Half of the treated group had evidence of periostitis. Discontinuation of voriconazole in patients with periostitis resulted in improved pain and a reduction in alkaline phosphatase and fluoride levels.
DISCUSSION
In addition to fluorosis and voriconazole, other causes of diffuse periostitis include primary and secondary hypertrophic osteoarthropathy, thyroid achropachy, venous stasis, leukemia, and other medications (vitamin A, prostaglandin) [17] . The clinical history is helpful in including or excluding most of these diagnoses as part of the differential diagnosis, however, hypertrophic osteoarthropathy can be difficult to exclude. Indeed, in the earliest reports of voriconazole-induced periostitis, hypertrophic osteoarthropathy was the leading alternative consideration and it was initially hypothesized that the two processes had the same pathophysiological mechanism [7] . Of note, however, voriconazole-induced periostitis can often be distinguished from hypertrophic osteoarthropathy by more diffuse involvement (as opposed to predominantly long bone involvement), the absence of clubbing, and universally elevated alkaline phosphatase [7] . Thyroid achropachy predominantly involves the metacarpals/metatarsals with a spiculated, lacy appearance. Venous stasis is usually seen in the lower extremities, and can have associated phleboliths/cellulitis. Bony leukemia in adults is most often seen in the axial skeleton with smooth, lamellated periosteal reaction [17] .
Voriconazole-induced periostitis is an important etiology of painful diffuse periostitis in immunocompromised patients characterized by dense, irregular, diffuse periostitis and increased uptake on Tc-99m MDP whole body bone scans. Clinicians and radiologists should carefully correlate with the clinical history in the setting of diffuse bony changes, particularly in immunocompromised patients. 
